Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 15 Paraganglioma 4 Meningioma 4 Carcinoma, Neuroendocrine 4 Pheochromocytoma 3 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Medullary 2 Carcinoid Tumor 2 Somatostatinoma 1 Serotonin Syndrome 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Hypertension 1 Disease Progression 1 Carcinoma, Merkel Cell 1 Carcinoid Heart Disease 1 Breast Neoplasms 1 Advanced Lung Neuroendocrine Tumor 1 Adenoma, Islet Cell 1

Interventions

Capecitabine 5 Temozolomide 4 Octreotide 3 Magnetic Resonance Spectroscopy 2 Leucovorin 2 Fluorouracil 2 Everolimus 2 Cisplatin 2 Bortezomib 2 Biological Therapy 2 Bevacizumab 2 vatalanib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 regorafenib 1 pentetreotide 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 batifiban 1 antineoplaston AS 2-1 1 antineoplaston A10 1 aflibercept 1 Thalidomide 1 Sunitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Somatostatinoma × lutetium Lu 177 dotatate × Clear all

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡